Skip navigation

Novaliq GmbH

Transforming Ocular therapeutics


Novaliq GmbH

Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics. All first- and best-in-class ocular therapeutics are based on the patented EyeSol® technology.  EyeSol® is the first and only water-free technology that overcomes the limitations of water-free eyedrops, improving the topical bioavailability, stability, and safety of traditionally unstable pharmaceutical ingredients. Semifluorinated alkanes (SFAs) form the basis for EyeSol® - scientific know-how made in Germany. 

Care Competences

  • Worldwide first water-free drug delivery technology (EyeSol®) overcoming limitations of water-based    eyedrops
  • High product-development competence and integrated processes along the entire value-chain (from the development of the fomulation, the preclinical and clinical stages, all the way to the market)
  • Industry-leading product pipeline for Dry Eye Disease based on several new mechanisms of action (MoAs)
  • Significant platform value captured in extensive early stage pipeline in glaucoma and retinal diseases
  • Intensive and integrative, academic cooperation in the therapeutic area 




More Informations

Novaliq GmbH

Im Neuenheimer Feld 515

69120 Heidelberg